Investor Presentaiton slide image

Investor Presentaiton

Global & Diverse Revenue Base FY19 Revenue US$8.5B Immunoglobulins $3,543m Seqirus $1,196m Specialty $1,572m Haemophilia Australia 8% Albumin $1,018m 11 | Driven by Our Promiseā„¢ $1051m North America 49% ROW 6% Asia 11% Europe 26% CSL
View entire presentation